• BMS-777607: c-Met Inhibitor for Platelet and Cancer Research

  2026-06-20

  BMS-777607 empowers researchers to precisely inhibit MET signaling, enabling both advanced cancer metastasis models and optimized hiPSC-derived platelet production. This guide details actionable protocols, troubleshooting insights, and the latest innovations for maximizing reproducibility with this selective c-Met inhibitor.

• ASB3 E3 Ligase Suppresses Innate Immunity via MAVS Degradati

  2026-06-19

  This study identifies ASB3 as a novel E3 ubiquitin ligase that downregulates antiviral innate immunity by targeting MAVS for K48-linked polyubiquitination and proteasomal degradation. These findings clarify a previously unrecognized host regulatory mechanism that modulates interferon signaling during RNA virus infection, with implications for understanding viral immune evasion and host-pathogen interactions.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-19

  Schwartz’s dissertation introduces a refined in vitro framework that distinguishes between proliferative arrest and cell death when evaluating anti-cancer drug responses. This nuanced approach reveals that most agents, including angiogenesis inhibitors, have distinct effects on growth and viability. The findings provide critical methodological guidance for designing and interpreting drug response assays in cancer biology.

• Angiotensin II: Mechanistic Depth and Translational Horizons

  2026-06-18

  Explore the mechanistic and translational power of Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) in cardiovascular research. This article integrates advanced biological rationale, protocol guidance, and the latest evidence linking Angiotensin II-induced pathways to heart failure metabolism, offering strategic insight for translational researchers seeking to bridge experimental rigor and clinical relevance.

• Reactive Oxygen Species Assay Kit: Advanced Redox Applicatio

  2026-06-18

  The APExBIO Reactive Oxygen Species Assay Kit (DHE) empowers researchers to quantify intracellular superoxide with precision, supporting cutting-edge studies in oxidative stress, apoptosis, and redox signaling. Practical protocol enhancements and troubleshooting strategies ensure robust, reproducible results for both foundational and translational studies.

• hiPSC-Derived Intestinal Organoids for Human Pharmacokinetic

  2026-06-17

  This study presents a streamlined protocol for generating intestinal organoids from human induced pluripotent stem cells (hiPSCs) with high proliferative and differentiation capacity. The approach promises improved models for drug absorption and metabolism studies, addressing key limitations of animal and transformed cell line systems.

• ATRX-Deficient Glioma: Enhanced Sensitivity to PDGFR Inhibit

  2026-06-17

  This study identifies a heightened vulnerability of ATRX-deficient high-grade glioma cells to selective PDGFR and RTK inhibition, suggesting ATRX status as a critical biomarker for targeted therapy approaches. The work provides mechanistic insights and supports integration of ATRX mutation screening into clinical trial design for glioblastoma.

• Anlotinib Inhibits Tumor Angiogenesis via VEGFR2, PDGFRβ, FG

  2026-06-16

  This study demonstrates that Anlotinib hydrochloride is a potent multi-target tyrosine kinase inhibitor that blocks angiogenesis by suppressing VEGFR2, PDGFRβ, and FGFR1 signaling. The findings establish its superior efficacy over established TKIs in inhibiting endothelial cell migration and capillary tube formation, providing mechanistic clarity for its use in cancer research.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-06-16

  CX-5461, a selective RNA polymerase I inhibitor from APExBIO, offers cancer researchers a powerful tool to dissect ribosome biogenesis, induce autophagy, and overcome chemoresistance in solid tumors. This article delivers actionable protocols, troubleshooting strategies, and applied insights anchored in recent high-impact studies.

• Lipo3K Transfection Reagent: Unlocking High-Efficiency Assay

  2026-06-15

  Lipo3K Transfection Reagent delivers exceptional transfection efficiency—even in challenging cell types—thanks to its dual-component system and low cytotoxicity. Its flexibility powers advanced gene expression and RNA interference workflows, making it the go-to lipid transfection reagent for researchers tackling complex cellular models.

• Standardized Whole-Blood Stimulation Reveals Metabolic Immun

  2026-06-15

  This study establishes a robust protocol for analyzing human immune responses via standardized whole-blood stimulation with metabolic modulation. The protocol enables precise evaluation of how targeted metabolic interventions alter cytokine production, offering a valuable foundation for immunometabolic and translational research.

• Nelfinavir Mesylate: Precision HIV-1 Protease Inhibition & F

  2026-06-14

  Explore how Nelfinavir Mesylate, a potent HIV-1 protease inhibitor, advances research in antiretroviral therapy and ferroptosis modulation. This article delivers a deep dive into its mechanism, assay design, and unique translational potential for HIV infection and beyond.

• Monomeric Amyloid Beta Modulates Microglia in Brain Developm

  2026-06-13

  Kwon et al. (2024) identify a novel signaling pathway by which monomeric amyloid beta acts as a negative regulator of microglial activation during mouse neocortical development. These findings expand the functional landscape of amyloid beta beyond its pathological roles, suggesting that depletion of its monomeric form may contribute to neurodevelopmental and neurodegenerative disorders.

• Carrier-Free Triterpene Prodrugs for Targeted OSCC Therapy

  2026-06-12

  This study presents a novel, carrier-free prodrug strategy utilizing self-assembled triterpene derivatives for the targeted chemotherapy of oral squamous cell carcinoma (OSCC). The approach leverages ROS-responsive linkers and dual triterpene synergy to achieve selective drug release and enhance therapeutic efficacy, offering a promising direction for natural product-based chemotherapeutics with minimized systemic toxicity.

• Reliable Anti-Angiogenic Assays with Anlotinib Hydrochloride

  2026-06-12

  This article delivers scenario-driven, evidence-based guidance for leveraging Anlotinib hydrochloride (SKU C8688) in advanced cell viability and angiogenesis assays. Drawing on literature-backed data and real-world workflow challenges, it demonstrates how researchers can achieve reproducibility, high sensitivity, and robust experimental outcomes with APExBIO’s Anlotinib hydrochloride.

16359 records 1/1091 page Next 12345 下5页 Last page